BofA has initiated coverage of Candel Therapeutics (CADL) with a buy rating, citing the potential of its immunotherapy drug candidates CAN-2409 and CAN-3110. Read more here.

Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for ...

BIS issued an Interim Final Rule that amends the Export Administration Regulation (EAR) to address dual use export ...

Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...

Also, transgender, queer, and intersex people were removed from State Department travel advisories. What was previously an advisory page for LGBTQI+ travelers has been renamed LGB Travel Information.

This article was originally published in our sister publication, The Stranger.—eds] When Joe Biden was President, trans ...

Shares of Candel Therapeutics Inc. (CADL) surged over 9% on Friday morning, reaching their highest level in nearly a month ...

SOUTH SAN FRANCISCO, CA, USA I 06, 2025 I Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 ...

Research on plant bioactive compounds has gained significant attention due to their potential health benefits and therapeutic properties. These compounds, ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Agriculture today faces unprecedented challenges due to climate change, which has notably impacted crop productivity through altered weather patterns, ...